Ozempic Shows Lower Heart Risk Than Mounjaro
A new real world study shows adults with type 2 diabetes taking an escalated dose of Ozempic experienced a lower risk of major cardiovascular events compared to patients switching to Mounjaro. The findings were presented at a medical meeting in Milan.
Xurve View
Insights:
Xurve View
NOVO NORDISK A/S-B reported that its diabetes drug Ozempic delivered a 6% lower risk of cardiovascular events compared to rival treatments. The findings emerged during a Tuesday presentation in Italy at a major medical gathering. The data arrives as drug makers vie for market share in the United States obesity sector.
